LuciMito

Description

COMPOSITION:

Each tablet contains Mitotane……………500 mg

INDICATION:

LUCIMITO is indicated for the treatment of patients with inoperable, functional or nonfunctional, adrenal cortical carcinoma.

DOSAGE AND USE:

The recommended initial dose of LUCIMITO is 2 g to 6 g orally, in three or four divided doses per day. Increase doses incrementally to achieve a blood concentration of 14 to 20 mg/L, or as tolerated. LUCIMITO is a cytotoxic drug. Follow applicable special handling and disposal procedures.

Tablets should be swallowed whole & not chewed or crushed.

STORAGE:

in a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children.

Do not administer LUCIMITO during Pregnancy and Lactation.